التفاصيل البيبلوغرافية
| العنوان: |
LBMON62 Central Diabetes Insipidus From A Patients’ Perspective- From Management To Psychological Co-morbidities And Re-naming Of The Condition |
| المؤلفون: |
Atila, Cihan, Loughrey, Paul Benjamin, Garrahy, Aoife, Winzeler, Bettina, Refardt, Julie, Gildroy, Patricia, Tarig Hamza, Malak El Tahra, Pal, Aparna, Thompson, Chris John, Verbalis, Joseph G, Hunter, Steven J, Levy, Miles J, Mark, Sherlock, Karavitaki, Niki, Newell-Price, John D C, Wass, John A H, Christ-Crain, Mirjam |
| المصدر: |
J Endocr Soc |
| بيانات النشر: |
Oxford University Press |
| سنة النشر: |
2022 |
| مصطلحات موضوعية: |
Neuroendocrinology and Pituitary, demo, socio |
| الوصف: |
BACKGROUND: Central diabetes insipidus (cDI) is a rare neuroendocrine condition characterized by deficiency of arginine vasopressin. Data about treatment-related side effects, psychological co-morbidities, and incidence of wrong management due to confusion with diabetes mellitus (DM) are scarce and limited to small studies. Furthermore, increasing interest has arisen on a potential need for re-naming the condition. METHODS: Web-based anonymous survey, developed by a team of endocrinologists and patient representatives covering issues from management of the condition and quality of life to lack of awareness amongst medical professionals. Patients were provided with the link to the online survey either via their physician during routine check-ups or the homepages of the UK Pituitary Foundation, Pituitary World News, Facebook group 'Got Diabetes Insipidus?', and Pituitary Society. Findings: In total, 1034 patients with cDI, 47%(n=488) with isolated posterior and 53%(n=546) with combined anterior/posterior pituitary dysfunction, participated. Median [IQR] age was 42[32, 53]. Duration of cDI was 9. 0[3. 0, 19. 0] years and its aetiologies were idiopathic 30%(n=315), tumors/cysts (pre-surgical 21%(n=217), post-surgical 25%(n=254)), inflammatory/autoimmune 6%(n=61), infiltrative diseases 6%(n=62), genetic 4%(n=44), head trauma 3%(n=34), and other causes 5%(n=47). Ninety-six percent (n=994) were on desmopressin therapy - oral tablets 56%(n=575), nasal spray 23%(n=233), and sublingual tablets 12%(n=126). Among these, 26%(n=273) experienced hyponatremia at least once whilst on desmopressin. Patients who routinely omitted desmopressin to allow aquaresis had a significantly lower risk of hyponatremia compared to those not aware of this approach (OR 0.63; 95%-CI 0.42-0.92; p<0. 018). Sixty-four percent (n=660) reported low quality of life with 6[4-7] out of 10 points on a visual analogue scale. Thirty-six percent (n=369, equally prevalent in isolated posterior and combined pituitary dysfunction) experienced psychological . |
| نوع الوثيقة: |
text |
| اللغة: |
English |
| Relation: |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707312/ |
| الاتاحة: |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707312/ |
| Rights: |
undefined |
| رقم الانضمام: |
edsbas.5F5463A0 |
| قاعدة البيانات: |
BASE |